{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:22:32Z","timestamp":1776349352695,"version":"3.51.2"},"reference-count":25,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.3892\/mmr.2017.7024","type":"journal-article","created":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T08:43:19Z","timestamp":1500280999000},"page":"3600-3605","source":"Crossref","is-referenced-by-count":19,"title":["Knockdown of JARID2 inhibits the proliferation and invasion of ovarian cancer through the PI3K\/Akt signaling pathway"],"prefix":"10.3892","volume":"16","author":[{"given":"Jian","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangquan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suping","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,7,17]]},"reference":[{"key":"key20180108002634_b1-mmr-16-03-3600","first-page":"24","article-title":"Genital cancers in women: Ovarian cancer","volume":"438","author":"Kuznia","year":"2015","journal-title":"FP Essent"},{"key":"key20180108002634_b2-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1006\/gyno.2000.6017","article-title":"Elderly ovarian cancer: Treatment with mitoxantrone-carboplatin","volume":"80","author":"Nicoletto","year":"2001","journal-title":"Gynecol Oncol"},{"key":"key20180108002634_b3-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): A randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"key":"key20180108002634_b4-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1470-2045(02)00847-1","article-title":"Part II: Chemotherapy for epithelial ovarian cancer-treatment of recurrent disease","volume":"3","author":"Harries","year":"2002","journal-title":"Lancet Oncol"},{"key":"key20180108002634_b5-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"h4443","DOI":"10.1136\/bmj.h4443","article-title":"Diagnosis of ovarian cancer","volume":"351","author":"Sundar","year":"2015","journal-title":"BMJ"},{"key":"key20180108002634_b6-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12885-015-1277-y","article-title":"Management and prognosis of patients with ovarian sex cord tumor with annular tubules: A retrospective study","volume":"15","author":"Qian","year":"2015","journal-title":"BMC Cancer"},{"key":"key20180108002634_b7-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1074\/jbc.M804994200","article-title":"A jumonji (Jarid2) protein complex represses cyclin D1 expression by methylation of histone H3-K9","volume":"284","author":"Shirato","year":"2009","journal-title":"J Biol Chem"},{"key":"key20180108002634_b8-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.molcel.2014.12.020","article-title":"Jarid2 Methylation via the PRC2 complex regulates H3K27me3 deposition during cell differentiation","volume":"57","author":"Sanulli","year":"2015","journal-title":"Mol Cell"},{"key":"key20180108002634_b9-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/ncb2065","article-title":"Jarid2 is a PRC2 component in embryonic stem cells required for multi-lineage differentiation and recruitment of PRC1 and RNA Polymerase II to developmental regulators","volume":"12","author":"Landeira","year":"2010","journal-title":"Nat Cell Biol"},{"key":"key20180108002634_b10-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.cell.2009.12.002","article-title":"Jarid2\/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells","volume":"139","author":"Peng","year":"2009","journal-title":"Cell"},{"key":"key20180108002634_b11-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/onc.2013.46","article-title":"JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells","volume":"33","author":"Walters","year":"2014","journal-title":"Oncogene"},{"key":"key20180108002634_b12-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"e115684","DOI":"10.1371\/journal.pone.0115684","article-title":"JARID2 is involved in transforming growth factor-beta-induced epithelial-mesenchymal transition of lung and colon cancer cell lines","volume":"9","author":"Tange","year":"2014","journal-title":"PLoS One"},{"key":"key20180108002634_b13-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"8355","DOI":"10.1038\/ncomms9355","article-title":"Genome-wide association study identifies new susceptibility loci for adolescent idiopathic scoliosis in Chinese girls","volume":"6","author":"Zhu","year":"2015","journal-title":"Nat Commun"},{"key":"key20180108002634_b14-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"40266","DOI":"10.18632\/oncotarget.9733","article-title":"JARID2 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition through PTEN\/AKT signaling","volume":"7","author":"Lei","year":"2016","journal-title":"Oncotarget"},{"key":"key20180108002634_b15-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-tie quantitative PCR and the 2(\u2212Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20180108002634_b16-mmr-16-03-3600","first-page":"1973","article-title":"Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer","volume":"24","author":"Li","year":"2004","journal-title":"Anticancer Res"},{"key":"key20180108002634_b17-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc3447","article-title":"Regulatory networks defining EMT during cancer initiation and progression","volume":"13","author":"De Craene","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"key20180108002634_b18-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10555-008-9169-0","article-title":"EMT, the cytoskeleton, and cancer cell invasion","volume":"28","author":"Yilmaz","year":"2009","journal-title":"Cancer Metast Rev"},{"key":"key20180108002634_b19-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.cellsig.2006.05.019","article-title":"Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway","volume":"18","author":"Meng","year":"2006","journal-title":"Cell Signal"},{"key":"key20180108002634_b20-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/gcc.20883","article-title":"Frequent genetic abnormalities of the PI3K\/AKT pathway in primary ovarian cancer predict patient outcome","volume":"50","author":"Huang","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"key20180108002634_b21-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canlet.2012.08.016","article-title":"The PI3K\/Akt\/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells","volume":"326","author":"Lau","year":"2012","journal-title":"Cancer Lett"},{"key":"key20180108002634_b22-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","article-title":"Targeting the PI3K-Akt pathway in human cancer: Rationale and promise","volume":"4","author":"Luo","year":"2003","journal-title":"Cancer Cell"},{"key":"key20180108002634_b23-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: Navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"key20180108002634_b24-mmr-16-03-3600","first-page":"2172","article-title":"The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines","volume":"63","author":"Grille","year":"2003","journal-title":"Cancer Res"},{"key":"key20180108002634_b25-mmr-16-03-3600","doi-asserted-by":"crossref","first-page":"25520","DOI":"10.18632\/oncotarget.4550","article-title":"The PI3K\/AKT\/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines","volume":"6","author":"Bai","year":"2015","journal-title":"Oncotarget"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"language":"en","deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T01:06:32Z","timestamp":1515373592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mmr.2017.7024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,7,17]]},"published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.3892\/mmr.2017.7024"],"URL":"https:\/\/doi.org\/10.3892\/mmr.2017.7024","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}